AIVC recommendations for the composition of influenza vaccine for Australia in 2017
The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 13th October 2016, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2017. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2015-2016 vaccines, and the availability of candidate vaccines viruses and reagents.
The committee recommended that the TGA should adopt the September 2016 WHO recommendations;
- the trivalent influenza vaccine components for the Australian 2017 influenza season should contain the following:
- A (H1N1): an A/Michigan/45/2015 (H1N1)pdm09 like virus
- A (H3N2): an A/Hong Kong/4801/2014 (H3N2) like virus
- B: a B/Brisbane/60/2008 like virus
- the quadrivalent influenza vaccine for the Australian 2017 influenza season should contain the trivalent influenza vaccine components listed above, and the additional B strain:
- B: a B/Phuket/3073/2013 like virus.
The AIVC recommendation for the composition of influenza vaccines for Australia in 2017 introduces a new A (H1N1)pdm09 like virus strain when compared to the composition of the trivalent and quadrivalent vaccines for Australia in 2016.
The TGA has accepted the recommendations of the AIVC.
The TGA considers the following viruses or reassortants are suitable vaccine strains:
- those as listed on the WHO Influenza vaccine web pages: Influenza vaccine viruses and reagents for H1N1, H3N2 and B viruses.
If other candidate vaccine viruses or reagents become available their suitability for use should be discussed with the TGA by emailing firstname.lastname@example.org.